PT1229047E - Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao - Google Patents

Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao

Info

Publication number
PT1229047E
PT1229047E PT02007831T PT02007831T PT1229047E PT 1229047 E PT1229047 E PT 1229047E PT 02007831 T PT02007831 T PT 02007831T PT 02007831 T PT02007831 T PT 02007831T PT 1229047 E PT1229047 E PT 1229047E
Authority
PT
Portugal
Prior art keywords
fuseous
antagonists
receptors
utilization
processes
Prior art date
Application number
PT02007831T
Other languages
English (en)
Portuguese (pt)
Inventor
George D Yancopoulos
Stahl Neil
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT1229047E publication Critical patent/PT1229047E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02007831T 1998-09-25 1999-09-22 Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao PT1229047E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
PT1229047E true PT1229047E (pt) 2005-03-31

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02007831T PT1229047E (pt) 1998-09-25 1999-09-22 Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao

Country Status (19)

Country Link
US (2) US6472179B2 (https=)
EP (3) EP1115876B1 (https=)
JP (1) JP3902728B2 (https=)
CN (1) CN100345970C (https=)
AT (2) ATE283365T1 (https=)
AU (1) AU758970C (https=)
BE (1) BE2010C021I2 (https=)
CA (1) CA2345109C (https=)
DE (3) DE69922269T2 (https=)
DK (1) DK1229047T3 (https=)
ES (2) ES2233733T3 (https=)
FR (1) FR10C0025I2 (https=)
HK (1) HK1045847B (https=)
IL (2) IL142103A0 (https=)
NO (2) NO329976B1 (https=)
NZ (1) NZ510720A (https=)
PL (1) PL201246B1 (https=)
PT (1) PT1229047E (https=)
WO (1) WO2000018932A2 (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
JP4660062B2 (ja) 2000-06-16 2011-03-30 アステリオン・リミテッド 結合剤
ES2381650T3 (es) 2000-08-08 2012-05-30 Zymogenetics, Inc. Receptores de citoquinas Zcytor11 solubles
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
US20050118683A1 (en) * 2003-06-11 2005-06-02 Wood Clive R. Method for producing a polypeptide
EP1648940B1 (en) * 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP1668133A4 (en) * 2003-09-05 2007-08-29 Ca Nat Research Council BISPIRALEE HYBRID PROTEIN WITH DOMAINS OF CELL RECEPTORS
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
EP1750746A1 (en) 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
PT1778723E (pt) * 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
ATE399868T1 (de) * 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
DK2229956T3 (da) * 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
JP4898691B2 (ja) 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
CN112457389A (zh) * 2005-11-23 2021-03-09 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) * 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
DK1873166T3 (da) 2006-06-30 2010-12-20 Conaris Res Inst Ag Forbedrede sgp 130Fc-dimerer
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
EP2074209A2 (en) * 2006-07-28 2009-07-01 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
WO2008051496A2 (en) * 2006-10-20 2008-05-02 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008093756A1 (ja) * 2007-01-30 2008-08-07 Niigata University 生物学的製剤
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP2011502163A (ja) * 2007-10-31 2011-01-20 ザ スクリプス リサーチ インスティテュート 持続性ウイルス感染を治療するための併用療法
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2326670A4 (en) * 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
SG10201703067QA (en) 2008-11-26 2017-05-30 Amgen Inc Variants Of Activin IIB Receptor Polypeptides And Uses Thereof
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
JP2014519480A (ja) 2011-04-15 2014-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌で使用される抗ｉｌ−１ｒ１阻害物質
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
AU2013357427B2 (en) * 2012-12-10 2017-08-31 Universiteit Gent Novel Interleukin-33 inhibitors
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
JP6225197B2 (ja) 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ ＩＬ−１β阻害剤組成物およびその使用
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
LT3226888T (lt) 2014-12-01 2021-05-25 Ferring B.V. Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
RS65665B1 (sr) * 2014-12-01 2024-07-31 Ferring Bv Selektivne kompozicije inhibitora il-6-trans-signalizacije
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
AU2016261854B2 (en) * 2015-05-12 2022-05-26 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DK0643719T3 (da) * 1992-03-09 1999-06-28 Ludwig Inst Cancer Res Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
EP0693084A4 (en) * 1993-04-06 1999-06-02 Hutchinson Fred Cancer Res CHIMERAL CYTOKINE RECEPTORS IN LYMPHOCYTE
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
DE69434934D1 (de) * 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US6077947A (en) * 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
EP1047781B1 (en) * 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors

Also Published As

Publication number Publication date
CN100345970C (zh) 2007-10-31
ES2233733T3 (es) 2005-06-16
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
WO2000018932A3 (en) 2000-11-02
NO20011513L (no) 2001-05-25
FR10C0025I1 (https=) 2010-05-21
PL201246B1 (pl) 2009-03-31
FR10C0025I2 (fr) 2011-04-01
US6472179B2 (en) 2002-10-29
EP1115876A2 (en) 2001-07-18
CA2345109C (en) 2012-12-18
AU6499499A (en) 2000-04-17
DE69932832T2 (de) 2007-02-08
AU758970B2 (en) 2003-04-03
JP2002525119A (ja) 2002-08-13
IL142103A (en) 2007-07-04
EP1229047A2 (en) 2002-08-07
PL348529A1 (en) 2002-06-03
CN1357049A (zh) 2002-07-03
NO329976B1 (no) 2011-01-31
BE2010C021I2 (https=) 2018-12-04
HK1045847A1 (en) 2002-12-13
NO2011003I2 (https=) 2011-04-11
HK1035377A1 (en) 2001-11-23
JP3902728B2 (ja) 2007-04-11
ATE336583T1 (de) 2006-09-15
US20020164690A1 (en) 2002-11-07
IL142103A0 (en) 2002-03-10
WO2000018932A9 (en) 2000-08-31
EP1405915A1 (en) 2004-04-07
NZ510720A (en) 2003-11-28
NO20011513D0 (no) 2001-03-23
EP1115876B1 (en) 2006-08-16
WO2000018932A2 (en) 2000-04-06
EP1229047B1 (en) 2004-11-24
AU758970C (en) 2007-05-03
DE69922269T2 (de) 2005-12-01
NO2011003I1 (no) 2011-05-02
DE69922269D1 (de) 2004-12-30
HK1045847B (en) 2005-03-24
EP1229047A3 (en) 2002-10-02
CA2345109A1 (en) 2000-04-06
ES2267300T3 (es) 2007-03-01
US20020012962A1 (en) 2002-01-31
DK1229047T3 (da) 2005-02-21
ATE283365T1 (de) 2004-12-15
DE122010000023I1 (de) 2012-04-26

Similar Documents

Publication Publication Date Title
PT1229047E (pt) Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao
IL168050A (en) Il-1 receptor based antagonists and methods of making them and reagents for use therein
ATE445642T1 (de) Trennung von polypeptiden mit einer racemisierten aminosäure
EA200401591A1 (ru) Керамические аноды и способ их изготовления
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
WO2002078524A3 (en) Translational profiling
TR199902512T2 (xx) Osteoprotegerin ba�lay�c� proteinler ve resept�rler.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE325865T1 (de) Isolierung von sezernierte proteine exprimierenden zellen
ATE474852T1 (de) Nukleinsäuren, die für einen an ein g-protein gekoppelten, an der sensorischen transduktion beteiligten rezeptor kodieren
ATE336578T1 (de) Nukleinsäurebindungsproteine
DE50108680D1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
IS2786B (is) Prótín sem bindast viðtaka Nogo
EP1589106A4 (en) ADIPONEKTIN RECEPTOR AND GENERATING ENCODER
CY1109207T1 (el) Διαδικασια εχινοκανδινης
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
DK1572133T3 (da) Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor
AR019862A1 (es) Una proteina-1 de union a angiostatina (abp-1) de mamifero aislada, una molecula de acido nucleico aislada que la codifica, un vector que la comprende, una celula recombinante, un anticuerpo o fragmento de anticuerpo, un metodo de rastreo, uso de las proteinas.
ATE494550T1 (de) Neues screening-verfahren
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
ATE392480T1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide